Clinical Guidelines for Breast Cancer Control and Management

Objectives

Provide national clinical standards to support South Africa’s Breast Cancer Prevention and Control Policy, reducing breast cancer incidence, morbidity and mortality through prevention, early detection, timely diagnosis, equitable treatment, survivorship support, palliative care, follow-up, surveillance, data and research.[1][2]The framework aligns breast cancer action with Sustainable Development Goal 3, the National Development Plan 2030, the emerging National Health Insurance framework, and relevant sexual and reproductive health policies.[3]

• Improve breast awareness, healthy lifestyle choices, understanding of risk factors, symptom recognition and prompt presentation, while addressing myths, stigma and inequities in access to care.[2][4]
• Strengthen early detection through community education, clinical breast examination, risk assessment, referral pathways and appropriately equipped breast-care facilities.[5][3]
• Reduce delays to assessment, diagnosis and treatment, reduce the stage at treatment, improve survival, and improve quality of life during survivorship, recurrence and palliation.[5]
• Ensure equitable access to a tiered breast-care system in which Regional Breast Units provide diagnosis and appropriate surgery, and Specialist Breast Units provide comprehensive multidisciplinary diagnosis and treatment.[6][7][8]
• Provide personalised management for inherited and high-risk breast cancer through genetic counselling, testing, risk-based imaging, chemoprevention and prophylactic surgery where appropriate.[9]
• Deliver evidence-based surgery, systemic therapy, radiotherapy, rehabilitation, lymphoedema prevention and management, psychosocial support, and palliative care according to clinical need.[10][11][12][13][14]
• Strengthen data, cancer registration, monitoring, research and audit so that service quality, outcomes, incidence, survival and mortality can be measured over time.[1][15][2]

Care standards centre on patient-centred, culturally and linguistically appropriate decision-making, informed consent and treatment planning that reflects clinical evidence alongside patients’ preferences, circumstances and support needs.[16]Breast cancer follow-up aims to detect recurrence, monitor treatment response, manage complications, provide psychological and nutritional support, and reduce lymphoedema risk.[17]

Implementation

Implement the policy through an integrated patient pathway from community awareness and first contact through assessment, diagnosis, multidisciplinary treatment, rehabilitation, follow-up and return to community-based support.[1]Delivery relies on coordinated roles for the National Department of Health, provincial and local health services, Regional and Specialist Breast Units, primary care facilities, oncology services, laboratories, civil society organisations, private partners, communities and families.[18][19]

• Establish a hub-and-spoke model linking Regional Breast Units at primary or secondary level with Specialist Breast Units at tertiary or quaternary level, including interprovincial coordination where necessary.[20]
• Accredit proposed breast units against minimum standards and identify support required to address deficiencies in staffing, equipment and service capacity.[21]
• Operate one-stop diagnostic clinics that combine clinical assessment, imaging and tissue diagnosis where appropriate, enabling rapid allocation to malignant-disease, benign-disease or discharge pathways.[21][6]
• Provide direct or open access to breast clinics for appropriately symptomatic women, strengthen primary-care training, and maintain two-way communication between referring clinicians and breast units.[22][23]
• Use referral triage to provide specialist breast assessment within 21 days for high- or medium-suspicion presentations and within 62 days for low-suspicion presentations, with no patient waiting longer than 62 days.[20][22]
• Meet treatment standards including surgery or chemotherapy within 62 days of first health-system contact or 31 days of the decision to treat, and adjuvant radiotherapy within 60 days of surgery and no later than 90 days afterwards.[6][7]
• Require triple assessment through clinical evaluation, imaging and histological confirmation, supported by standardised pathology requests, synoptic reporting and multidisciplinary team review.[23][24]
• Convene multidisciplinary teams including surgery, medical and radiation oncology, pathology, radiology, supportive care and breast-care coordination, using in-person meetings, teleconferencing or videoconferencing as needed.[16]

Primary health-care delivery includes breast education, provider-initiated clinical breast examination for women over 40 attending primary health clinics every six months, systematic recording of results, immediate referral of abnormalities, and six-monthly risk assessment of eligible women using the High-5 method.[19][25]First-contact facilities should take a clinical history and perform breast examination before referring symptomatic patients to a Regional or Specialist Breast Unit, with referral urgency determined by findings.[26]

Workforce development combines train-the-trainer activity for community health workers and health promoters, online education for healthcare workers through the Breast Cancer Education Platform, accredited breast-care nursing development, and blended university-based breast assessment, navigation and survivorship courses.[4][27][28]Patient navigators, breast-care nurses and counsellors should help overcome psychological, communication, transport and socioeconomic barriers, coordinate referrals and results, support treatment decisions, and follow up missed appointments.[29]

Palliative care should begin from diagnosis of life-threatening illness and operate across hospital, clinic, community and home-based settings through multidisciplinary teams, with care intensity matched to functional status and changing physical, psychosocial and spiritual needs.[30][31]Rehabilitation and lymphoedema services should assess patients before treatment and at subsequent breast-unit visits, educate patients in risk reduction and self-care, document limb measurements, and refer complex cases for specialist therapy.[14][32]

Implementation should be supported by facility-level databases, monthly and annual service figures, population-based cancer registration, sentinel surveillance sites, vital statistics, case series and a monitoring and evaluation plan using selected input, process and outcome measures.[15][2]The framework requires audit of standards and outcomes, peer review of timeliness and quality, recording of multidisciplinary decisions, and assessment of navigation outcomes, although many extracts do not assign a single formal accountability body or specify complete reporting arrangements.[5][23][29]

Resource requirements include qualified staff, diagnostic imaging, pathology, surgery, theatre capacity, oncology, radiotherapy, medicines, telecommunication, transport support and functioning information systems.[33][20]The material identifies resource constraints and investment needs, but does not specify consolidated budgets, financing sources or monetary costings for implementation.[20][2]

Monitoring & Evaluation

The guidelines establish a broad monitoring and evaluation approach spanning service access, timeliness, clinical quality, patient outcomes, cancer surveillance and programme implementation. They prioritise early input and process measures because measurable cancer outcomes may take years to emerge, and call for existing health-data sources to be combined with new information infrastructure.[15][2]

• Monitor programme implementation and intervention impact, and audit breast-care standards and outcomes.[5]
• Measure facility activity through reliable monthly and annual figures from primary health-care facilities, Regional Breast Units, Specialised Breast Units and provincial oncology units.[15]
• Maintain patient databases at Specialised Breast Units and provincial oncology units to support clinical management, surveillance and research.[15]
• Establish population-based breast cancer incidence and mortality information through a national cancer registry, sentinel surveillance sites, clinician-collected case series and mortality data from the Department of Home Affairs and Statistics South Africa.[15][2]
• Develop a detailed monitoring and evaluation plan specifying data sources, reporting intervals, data flows, indicator definitions, collection methods and required monitoring resources in consultation with stakeholders and health services.[2]
• Select a limited set of input, process and outcome measures from routinely collected administrative and surveillance data, while aligning facility reporting with the National Indicator Dataset.[2]

Timeliness standards provide key operational performance measures across the referral, diagnostic and treatment pathway. Women with high or medium clinical suspicion should be assessed within 21 days and those with low suspicion within 62 days.[22]Suspicious symptoms require imaging within 14 days, while pathology services should provide breast-biopsy results within 10 days.[6][7]Surgery or chemotherapy should begin within 62 days of first health-system contact or 31 days of the decision to treat; adjuvant radiotherapy should start within 60 days of surgery and no later than 90 days afterwards.[6][7]

• Evaluate timeliness and quality standards through peer-review visits.[23]
• Accredit proposed Regional Breast Units and Specialised Breast Units against minimum standards, identifying support needed where standards are unmet.[21]
• Record clinical breast-examination results systematically and refer detected abnormalities for further assessment.[19]
• Record multidisciplinary team decisions and communicate outcomes to treating or referring clinicians; audit clinical issues, outcomes, patient experience and information provision.[16][22]
• Use synoptic pathology reporting to strengthen completeness, accuracy and extraction of treatment-relevant information.[24]
• Monitor navigation through care coordination, barrier removal, treatment adherence and emotional-support outcomes, including missed investigations or treatment appointments and loss to follow-up.[29]

Clinical follow-up and surveillance requirements are detailed for selected patient groups. Follow breast cancer patients every three months in the first two years, every six months in years three and four, and annually thereafter, with history, symptom assessment and physical examination at each visit.[17]Provide annual mammography after treatment for early and locally advanced breast cancer, while avoiding routine blood tests and imaging for asymptomatic patients.[17]High-risk genetic screening, trastuzumab treatment, neo-adjuvant therapy, palliative care, lymphoedema and rehabilitation also include specified clinical assessment and follow-up processes.[9][34][11][31][32][35]

The guidance includes accountability mechanisms through minimum service standards, accreditation, peer review, multidisciplinary review, audit and documentation, but does not consistently assign named institutions or officers responsibility for reporting, performance management or corrective action.[21][16][23][2]

Costing & Financing

The guidelines identify extensive resource requirements for breast cancer prevention, diagnosis, treatment, palliative care, rehabilitation, training and information systems, but provide almost no monetary costing or budget allocations.[1][33][2]

• Provide Regional and Specialised Breast Units with appropriately trained staff, diagnostic imaging, pathology, surgery, nursing, navigation, counselling, administration, teleconferencing and data-management capacity.[33][20][7]
• Allocate theatre, oncology, imaging and pathology capacity in proportion to breast-care workload; a service treating 100 breast-cancer patients annually should receive one full theatre-list day each week.[6]
• Address continuity-of-care constraints associated with staff shortages, equipment availability and maintenance, weak infrastructure, and patient transport, accommodation and household costs.[20]
• Invest in population-based cancer registration, sentinel surveillance and monitoring and evaluation infrastructure, without specifying the required budget or financing source.[2]
• Support training, patient navigation and community awareness activities, while recognising that the navigation pilot should establish its own scope, cost and implementation strategy before possible national roll-out.[29][4][27]
• Ensure availability of essential palliative-care medicines, including morphine, which is identified as the preferred strong opioid because of cost, availability and familiarity.[36][37]

Some interventions are explicitly constrained by affordability or resource scarcity. Breast reconstruction is not available to all patients because of extreme resource limitations.[10]Capecitabine is not recommended by the National Essential Medicines List Committee because of cost, although reassessment is advised if generic products become available.[38]Antibody therapy requires accurate human epidermal growth factor receptor 2 testing because it is costly and carries a small but significant risk of cardiac toxicity.[39]

No overall budget, programme costing, financing mechanism, funding allocation, quantified funding gap, donor contribution, resource-mobilisation target or economic assumption is specified for implementing the guidance.[1][2]